Uniqure NV (NASDAQ:QURE) SVP Maria E. Cantor sold 5,864 shares of the business’s stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $20.13, for a total transaction of $118,042.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Uniqure NV (NASDAQ:QURE) traded down $0.34 during trading hours on Wednesday, reaching $19.82. 538,165 shares of the company’s stock were exchanged, compared to its average volume of 443,600. The stock has a market cap of $610.46, a price-to-earnings ratio of -7.59 and a beta of 0.72. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.64 and a current ratio of 3.64. Uniqure NV has a 52 week low of $4.72 and a 52 week high of $21.35.

A number of large investors have recently added to or reduced their stakes in QURE. Mangrove Partners lifted its holdings in Uniqure by 167.4% in the 3rd quarter. Mangrove Partners now owns 106,634 shares of the biotechnology company’s stock valued at $1,024,000 after purchasing an additional 66,763 shares in the last quarter. FMR LLC lifted its holdings in Uniqure by 4.1% in the 2nd quarter. FMR LLC now owns 1,560,113 shares of the biotechnology company’s stock valued at $9,656,000 after purchasing an additional 61,650 shares in the last quarter. OxFORD Asset Management LLP acquired a new position in shares of Uniqure during the 3rd quarter valued at about $399,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Uniqure by 33.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock valued at $362,000 after acquiring an additional 14,659 shares during the last quarter. Institutional investors own 24.87% of the company’s stock.

Several equities analysts have issued reports on QURE shares. Zacks Investment Research cut shares of Uniqure from a “hold” rating to a “sell” rating in a research note on Wednesday, October 18th. Leerink Swann boosted their price objective on shares of Uniqure from $17.00 to $19.00 and gave the company an “outperform” rating in a research note on Friday, October 20th. Evercore ISI initiated coverage on shares of Uniqure in a research report on Tuesday, November 7th. They set an “outperform” rating and a $22.00 target price on the stock. Oppenheimer restated a “hold” rating on shares of Uniqure in a research report on Friday, November 24th. Finally, HC Wainwright initiated coverage on shares of Uniqure in a research report on Friday, December 1st. They set a “buy” rating and a $28.00 target price on the stock. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $20.00.

COPYRIGHT VIOLATION WARNING: This news story was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2018/01/03/uniqure-nv-qure-svp-sells-118042-32-in-stock.html.

Uniqure Company Profile

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.